{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:43:55Z","timestamp":1792165435461,"version":"4.4.0"},"reference-count":40,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["CHAN23Y5"],"award-info":[{"award-number":["CHAN23Y5"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["KOHLER23H0"],"award-info":[{"award-number":["KOHLER23H0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["ZEMANI20Y7"],"award-info":[{"award-number":["ZEMANI20Y7"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>A number of disease-modifying therapies have been introduced for people with cystic fibrosis (CF) over the past two decades. The cumulative effects of this changing landscape on cystic fibrosis\u2013related diabetes (CFRD) are unclear. We examined trends in CFRD epidemiology over time using data from the U.S. Cystic Fibrosis Foundation Patient Registry (CFFPR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>CFFPR data from 2003 to 2018 were queried to determine annual screening, incidence, and prevalence rates of CFRD. Individuals with incident CFRD were compared with individuals without CFRD. Survival analyses were performed to estimate the cumulative hazard of CFRD given predictors of interest over the 15 years of study. Data were also grouped into three time periods (2003\u20132008, 2009\u20132013, and 2014\u20132018) to investigate whether the hazard of developing CFRD varied over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>CFRD screening rates increased from 2003 to 2018, particularly in 10- to 18-year-olds. Although screening rates increased in adults, overall rates remained low. In 10- to 18-year-olds, the incidence of CFRD was stable over time, while incident cases in adults steadily decreased, approaching incident rates in adolescents. Despite this, the prevalence of CFRD has gradually increased in adults, likely reflecting increased longevity. Age, female sex, Black race, severe mutation class, liver disease, poorer lung function, pancreatic insufficiency, enteric feeds, and low and high BMI were all risk factors associated with CFRD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Findings support the need for the development of tailored CFRD screening algorithms and increased subspecialists to care for a growing population of adults with CF and CF-associated comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-0044","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T10:59:47Z","timestamp":1747306787000},"page":"1251-1259","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":14,"title":["Trends in Cystic Fibrosis\u2013Related Diabetes Epidemiology Between 2003 and 2018 From the U.S. Cystic Fibrosis Foundation Patient Registry"],"prefix":"10.2337","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8517-4012","authenticated-orcid":false,"given":"Celia L.","family":"Kohler","sequence":"first","affiliation":[{"name":"School of Medicine, University of Colorado Anschutz Medical Campus 1 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Vigers","sequence":"additional","affiliation":[{"name":"Biostatistics and Informatics, Colorado School of Public Health 2 , Aurora, CO"},{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus 3 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pyle","sequence":"additional","affiliation":[{"name":"Biostatistics and Informatics, Colorado School of Public Health 2 , Aurora, CO"},{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus 3 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus 3 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith T.","family":"Zemanick","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus 3 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Moran","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Minnesota School of Medicine 4 , Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Sagel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus 3 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-7672","authenticated-orcid":false,"given":"Christine L.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus 3 , Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"2026061713123731000_B1","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"2026061713123731000_B2","doi-asserted-by":"crossref","first-page":"1269139","DOI":"10.3389\/fendo.2023.1269139","article-title":"Pancreas and islet morphology in cystic fibrosis: clues to the etiology of cystic fibrosis-related diabetes","volume":"14","author":"Malik","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026061713123731000_B3","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/JOE-18-0468","article-title":"Survival in a bad neighborhood: pancreatic islets in cystic fibrosis","volume":"241","author":"Norris","year":"2019","journal-title":"J Endocrinol"},{"key":"2026061713123731000_B4","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"2026061713123731000_B5","unstructured":"Cystic Fibrosis Foundation (2019)\n          . Cystic Fibrosis Foundation Patient Registry - 2018 Annual Data Report. Available from https:\/\/www.cff.org\/sites\/default\/files\/2021-10\/2018-Annual-Report.pdf"},{"key":"2026061713123731000_B6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061713123731000_B7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"2026061713123731000_B8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jpeds.2004.12.039","article-title":"Epidemiology of cystic fibrosis-related diabetes","volume":"146","author":"Marshall","year":"2005","journal-title":"J Pediatr"},{"key":"2026061713123731000_B9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2337\/dc09-1215","article-title":"Diabetes as a determinant of mortality in cystic fibrosis","volume":"33","author":"Chamnan","year":"2010","journal-title":"Diabetes Care"},{"key":"2026061713123731000_B10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061713123731000_B11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2019.07.010","article-title":"The association of pediatric cystic fibrosis-related diabetes screening on clinical outcomes by center: a CF patient registry study","volume":"19","author":"Franck Thompson","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026061713123731000_B12","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1542\/peds.2012-4029","article-title":"Improving screening for cystic fibrosis-related diabetes at a pediatric cystic fibrosis program","volume":"132","author":"Kern","year":"2013","journal-title":"Pediatrics"},{"key":"2026061713123731000_B13","doi-asserted-by":"crossref","first-page":"e000183","DOI":"10.1136\/bmjdrc-2015-000183","article-title":"Improving performance in the detection and management of cystic fibrosis-related diabetes in the Mountain West Cystic Fibrosis Consortium","volume":"4","author":"Liou","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026061713123731000_B14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ppul.22988","article-title":"Improved screening for cystic fibrosis-related diabetes by an integrated care team using an algorithm","volume":"49","author":"Rayas","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"2026061713123731000_B15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026061713123731000_B16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026061713123731000_B17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcjd.2024.09.001","article-title":"Cystic fibrosis\u2013related diabetes: a first Canadian Clinical Practice Guideline","volume":"49","author":"Coriati","year":"2025","journal-title":"Can J Diabetes"},{"key":"2026061713123731000_B18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clin Nutr"},{"key":"2026061713123731000_B19","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jand.2020.03.015","article-title":"Academy of Nutrition and Dietetics: 2020 Cystic Fibrosis Evidence Analysis Center Evidence-Based Nutrition Practice Guideline","volume":"121","author":"McDonald","year":"2021","journal-title":"J Acad Nutr Diet"},{"key":"2026061713123731000_B20","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa1610187","article-title":"Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012","volume":"376","author":"Mayer-Davis","year":"2017","journal-title":"N Engl J Med"},{"key":"2026061713123731000_B21","article-title":"Glycemia and insulin secretion in cystic fibrosis two years after elexacaftor\/tezacaftor\/ivacaftor: PROMISE-ENDO","author":"Chan","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061713123731000_B22","doi-asserted-by":"crossref","first-page":"2042018820966428","DOI":"10.1177\/2042018820966428","article-title":"Retinopathy and microalbuminuria are common microvascular complications in cystic fibrosis-related diabetes","volume":"11","author":"Kempegowda","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2026061713123731000_B23","first-page":"100308","article-title":"Coronary artery disease in patients with cystic fibrosis\u2014a case series and review of the literature","volume":"30","author":"Sandouk","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"2026061713123731000_B24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026061713123731000_B25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","article-title":"Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single-center analysis","volume":"19","author":"Harindhanavudhi","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026061713123731000_B26","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2213-2600(23)00297-7","article-title":"Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026061713123731000_B27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026061713123731000_B28","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/adc.2010.208652","article-title":"Increased detection of cystic-fibrosis-related diabetes in Australia","volume":"96","author":"Rana","year":"2011","journal-title":"Arch Dis Child"},{"key":"2026061713123731000_B29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.10.009","article-title":"Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome; Olesen","volume":"19","author":"Olesen","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026061713123731000_B30","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jcf.2019.04.015","article-title":"Incidence and risk factors of paediatric cystic fibrosis-related diabetes","volume":"18","author":"Perrem","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026061713123731000_B31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026061713123731000_B32","unstructured":"Cystic Fibrosis Foundation\n          . Cystic Fibrosis Foundation Patient Registry - 2013 Annual Data Report. Bethesda, MD"},{"key":"2026061713123731000_B33","doi-asserted-by":"crossref","first-page":"e98240","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic fibrosis-related diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart","year":"2018","journal-title":"JCI Insight"},{"key":"2026061713123731000_B34","doi-asserted-by":"crossref","first-page":"1183288","DOI":"10.3389\/fendo.2023.1183288","article-title":"A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers","volume":"14","author":"Hicks","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026061713123731000_B35","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1210\/clinem\/dgab692","article-title":"The relationship between continuous glucose monitoring and OGTT in youth and young adults with cystic fibrosis","volume":"107","author":"Chan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061713123731000_B36","doi-asserted-by":"crossref","first-page":"e1444","DOI":"10.1210\/clinem\/dgab857","article-title":"Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis","volume":"107","author":"Scully","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061713123731000_B37","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1089\/jwh.2014.4985","article-title":"Gender differences in outcomes of patients with cystic fibrosis","volume":"23","author":"Harness-Brumley","year":"2014","journal-title":"J Womens Health (Larchmt)"},{"key":"2026061713123731000_B38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jcf.2024.07.018","article-title":"Association of race and ethnicity with the development of cystic fibrosis-related diabetes","volume":"24","author":"Rayas","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026061713123731000_B39","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1002\/ppul.27040","article-title":"Disparities in elexacaftor\/tezacaftor\/ivacaftor initiation in the US cystic fibrosis population","volume":"59","author":"Jordan","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026061713123731000_B40","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/7\/1251\/807373\/dc250044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/7\/1251\/807373\/dc250044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:12:49Z","timestamp":1781716369000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/48\/7\/1251\/158306\/Trends-in-Cystic-Fibrosis-Related-Diabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-0044","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}